Clinical Trial Update: A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 proof-of-concept trial of the GLA-SE adjuvant in Merkel cell carcinoma. The study was sponsored by Immune Desi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• GLA-SE (glucopyranosyl lipid adjuvant in stable emulsion)

Snippet

Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Merkel Cell Carcinoma | Phase 1 | Status: COMPLETED